Should You Buy Synopsys Stock While Its Cash Runs Far Ahead Of Its Profit

Synopsys (SNPS) sells the design software and the interface IP that chip makers need to get AI silicon built, and its stock has still gone backwards over the past year. At about $370 the shares sit at their 52-week low. Reported margins have fallen sharply over the past year. Free cash flow tells a different story, and the gap between cash and reported profit is the case worth arguing here.

Why Is Synopsys Stock At The Bottom Of Its Range?

Start with the honest part. The stock lost about 14% over the past year while the S&P 500 gained close to 17%. Reported net margin over the trailing twelve months is 11.4%, against 31.0% a year earlier.

The growth that management is selling arrives later. Multiphysics Fusion, the first joint Synopsys and Ansys solution, is not expected to contribute to EDA growth until 2027. Factory 2, the move from licensing alone to licensing plus royalties on customized IP, is still being discussed with multiple customers. On the fiscal Q3 2026 call an analyst pressed on a larger worry, whether AI-native chip design could one day bypass commercial EDA tools altogether.

What Is The Cash Telling You That Profit Is Not?

Over the trailing twelve months, free cash flow ran at about 255% of reported net income. The cash Synopsys collects is far larger than the profit it reports. Management then raised its fiscal 2026 free cash flow outlook to approximately $2.6 billion, after stronger collections and a cut to capital spending.

That cash comes off work already booked. Backlog was $10.9 billion at the end of fiscal Q3 2026. It held up even after the sale of the processor IP solutions business trimmed it.

Can Synopsys Afford To Wait For The Royalty Model?

On the cash flow, yes, though Synopsys ended fiscal Q3 2026 with about $10 billion of total debt against $3.6 billion of cash and short-term investments. The core business is not sitting still while Factory 2 is under discussion. EDA revenue rose 8.5% year over year in fiscal Q3 2026, helped by a record quarter in hardware-assisted verification. Management expects EDA growth to accelerate to double digits in the fourth quarter of fiscal 2026 and for the full year, and Design IP returned to growth.

So the case is narrow, and it should stay narrow. Reported margins are depressed and the new revenue is not here yet. What the cash says is that the business funding that wait is in better shape than the profit line suggests.

The cash does not settle the AI-native design worry, and that one has no number attached to it yet. If the appeal here is the marked-down price rather than the promise of 2027, the same question is worth putting to every stock that has already fallen this far.

So Would You Buy Synopsys For The Cash Alone?

Perhaps, but only if you are buying the cash and are honest that the rest is a wait. That distinction decides whether holding Synopsys is patience or hope. Owning one name through that wait puts the whole decision on a single company's execution. If you would rather not carry that alone, look at the Trefis High Quality Portfolio. That portfolio has a track record of outpacing the three major indices.